CGEN vs PD: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PD is the larger of the two ($1.19B market cap): the incumbent the market prices for continued execution (10.29x forward earnings, beta 0.95). CGEN is the smaller challenger ($173.35M), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, CGEN fits (beta 2.82). If you want the steadier ride, PD fits (beta 0.95).

CGEN vs PD: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCGENPDWhat it tells you
Market cap$173.35M$1.19BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-5.2310.29Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E4.697.48Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta2.820.95Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range22% of range76% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.085.07How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CGEN and PD affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CGEN and PD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CGEN and PD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Compugen (CGEN) do?

Compugen Ltd. is a clinical-stage immuno-oncology company based in Holon, Israel, listed on Nasdaq and the Tel Aviv Stock Exchange. Its edge has always been computational: a predictive discovery platform used to find new drug targets in the immune system. That platform produced the antibodies behind its pipeline. COM701 is a first-in-class antibody against PVRIG, which Compugen develops itself. COM902, an anti-TIGIT antibody, is the source of the TIGIT arm of rilvegostomig, the PD-1/TIGIT bispecific that AstraZeneca licensed and now runs in about 12 Phase 3 trials. GS-0321 (formerly COM503), an antibody that blocks IL-18 binding protein, was licensed to Gilead in late 2024 and is in Phase 1 dose escalation.

Full CGEN guide

What does PagerDuty (PD) do?

PagerDuty sells the software that wakes engineers up. When a payment system, a checkout flow or an internal API breaks, PagerDuty ingests the alert from monitoring tools, decides who is on call, escalates until a human acknowledges it, and coordinates the response through to a postmortem. Around that core it has added runbook automation (from its 2020 Rundeck purchase), an AIOps layer that groups noisy alerts into single incidents, customer service operations tooling, and more recently a set of agentic features: in November 2026 it unveiled Paige, an SRE agent, alongside a rebranded PD Reliability Platform and a PD Labs unit for open AI work in reliability engineering. Roughly 15,500 paying customers use it, of which about 884 spend more than ~$100,000 a year, and annual recurring revenue sits near ~$501 million.

Full PD guide

CGEN vs PD: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CGEN drivers: Rilvegostomig royalties at AstraZeneca; COM701 and the MAIA-ovarian readout.
  • PD drivers: Margin and cash generation from a flat revenue base; A new chief executive and a go-to-market reset.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The biggest risk is that the TIGIT class does not work well enough. For PD, the core problem is demand, not costs: dollar-based net retention of ~98% means the existing customer base is shrinking slightly net of expansion, so new logos are doing the work of holding revenue flat.

CGEN or PD: which should you pick?

If the story you believe is CGEN's (Rilvegostomig royalties at AstraZeneca), CGEN is the more direct way to own it; if it is PD's (Margin and cash generation from a flat revenue base), PD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CGEN and PD guides.

CGEN vs PD: the full fundamentals

CGEN. Traditional ratios do not describe Compugen well. The trailing P/E of ~4.7 looks cheap only because trailing revenue and profit include the ~$65 million December 2025 royalty sale to AstraZeneca; the recurring business generates ~$2 million to ~$4 million of revenue a quarter and a loss of ~$6 million to ~$8 million. The more useful lens is enterprise value: at ~$1.84 per share, the market places roughly ~$57 million on the pipeline above cash, about 2.1 times book equity. The five analysts tracked by Yahoo Finance have a mean target near $4.80 with a strong buy consensus, but for a company like this, valuation moves on trial data and partner news, not on quarterly earnings, so the cash balance and the burn rate are the figures that tend to anchor the share price between catalysts.

PD. Two numbers explain most of the debate around PD. Revenue growth under 1% with retention below 100% is what kept the multiple under ~2x sales through the summer, while a ~23.7% non-GAAP operating margin and real free cash flow are what kept a floor under it. At about $15.08 (November 20, 2026) the stock trades near 2.4x sales and about 10x analysts' forward EPS of ~$1.47, somewhat below the mid-October peak multiple. Consensus for fiscal 2027 is ~$1.36 of EPS on ~$494 million of revenue, so profitability is expected to do the improving, and the December 3 report will show whether that holds.

Headline figures (approximate, November 2026): CGEN shows share price ~$1.84 (Nov 20, 2026), market cap ~$174 million, revenue (ttm) ~$76 million (incl. ~$65 million one-time royalty sale); Q3 2026 ~$3.8 million, net income (ttm) ~$36 million (one-time driven); Q3 2026 loss ~$5.8 million; PD shows revenue (ttm) ~$495 million, q2 fy2027 revenue (quarter ended july 31, 2026) ~$124.4 million, up ~0.8% year over year, annual recurring revenue / net retention ~$501 million ARR, dollar-based net retention ~98%, profitability ~85% gross margin; GAAP operating margin ~6.8% (TTM); non-GAAP operating margin ~23.7% last quarter; non-GAAP diluted EPS ~$0.32 (est. ~$0.31).

The bottom line: CGEN vs PD

CGEN and PD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CGEN and PD exposure against your real portfolio. It is not an investment adviser.

Wondering how CGEN or PD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Compugen

Ask Walnut's AI anything about CGEN and see how it fits what you own.

FAQ

What is the difference between CGEN and PD?

+

Compugen Ltd. PagerDuty sells the software that wakes engineers up. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CGEN or PD the better stock?

+

Neither is universally better. PD is the larger incumbent; CGEN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CGEN or PD?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CGEN and PD?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CGEN vs PD?

+

CGEN: The biggest risk is that the TIGIT class does not work well enough. Roche, Merck and others discontinued TIGIT programs after disappointing late-stage results, and if rilvegostomig's Phase 3 trials follow that path, the royalty stream that underpins much of Compugen's value could shrink toward zero. Compugen also has no control over AstraZeneca's or Gilead's priorities, timelines or decisions to cut programs. COM701 is a single binary event: MAIA-ovarian, with only 62 patients, could show no meaningful benefit, and PVRIG has never been validated in a randomized trial. Rilvegostomig's first Phase 3 readout has also moved to the second half of 2027. Revenue is irregular and partner-driven, so headline profit in 2025 says little about the underlying business, which lost ~$5.8 million in Q3 2026 and ~$6 million to ~$8 million in earlier quarters. Having already sold part of its rilvegostomig royalties, Compugen has given up some upside in exchange for cash today. The stock traded at ~$1.84 on November 20, 2026, after a ~36% three-month fall, a level where Nasdaq's $1 minimum bid rule has bitten before (Compugen regained compliance in January 2024 after falling below it). As an Israeli company, it also carries currency and regional geopolitical exposure, and thin trading can make the shares move sharply on small news. Finally, if MAIA-ovarian succeeds, a larger registrational trial would cost far more than today's burn, which could mean dilution or a partnership on less favorable terms. PD: The core problem is demand, not costs: dollar-based net retention of ~98% means the existing customer base is shrinking slightly net of expansion, so new logos are doing the work of holding revenue flat. Seat-based pricing ties PagerDuty to engineering headcount at technology companies, a line item that has been cut repeatedly since 2023 and that AI coding tools may keep suppressing. Competitively, the pressure comes from bundling rather than from a better product: Datadog now ships its own on-call module, Atlassian folds Opsgenie capability into Jira Service Management, and both can price incident management as an add-on to a platform a customer already buys. Glancy Prongay & Murray announced a securities-fraud investigation in December 2025 after the November 25, 2025 results, when the shares fell about 23% on disclosure of weakening demand and retention, and while no class action complaint has been filed to date, the underlying facts it points at are the same growth facts above. Convertible debt sits against the cash balance (Yahoo Finance shows about ~$413 million of debt versus ~$470 million of cash and investments), so the gross cash figure overstates the net position, and any reader should check the current note terms in the latest 10-Q rather than assume them away. Valuation risk has also risen: even after a one-month pullback of about 14% the stock trades above the average analyst target of about $13.43, and the trailing P/E of about 7.5x flatters it because trailing net income of ~$186 million includes a single quarter of about $160 million in late 2025, far above the ~$5 million to ~$11 million of recent quarters.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CGEN or PD; figures are approximate and dated (as of November 2026). Verify current data before investing.